Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Triptonide and bortezomib synergistically inhibit multiple myeloma by enhancing DNA damage through blocking TRIP13-mediated DNA repair

Fen He, Hongyan Zhao, Maoyou Lu, Ruixin Gao, Siqi Wang, Yu Chen, Qianhao Li, Weihui Chen, Jiayu Liu, Wenya Pei, Xiuyun Tang, Jinyu Yan, Lijun Peng, Wen Zhou, Jiliang Xia

Blood (2025) 146 (Supplement 1): 2165.

https://doi.org/10.1182/blood-2025-2165

Published: 2025

Journal Articles

Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity

Pan-Yu Chen, Somenath Chowdhury, Sophia Qiqun Zeng, Dalya Ataca, Fleuriane Gallean, Bernice Matusow, Amanda Kohler, Gideon Bollag

Blood (2025) 146 (Supplement 1): 573.

https://doi.org/10.1182/blood-2025-573

Published: 2025

Journal Articles

High FDX1 expression enhances the sensitivity of multiple myeloma cells to elesclomol

Hongyan Zhao, Fen He, Ruixin Gao, Maoyou Lu, Siqi Wang, Yu Chen, Wenya Pei, Xiuyun Tang, Jinyu Yan, Qianhao Li, Weihui Chen, Jiayu Liu, Lijun Peng, Jiliang Xia

Blood (2025) 146 (Supplement 1): 7448.

https://doi.org/10.1182/blood-2025-7448

Published: 2025

Journal Articles

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Jennifer Woyach, Danielle Brander, Boyu Hu, Kerry Rogers, Zulfa Omer, Emily Curran, Deborah Stephens, Andrea Sitlinger, Yi Chen, Stephen Anthony, Yu Chen, Kewei Shang, John Byrd

Blood (2025) 146 (Supplement 1): 87.

https://doi.org/10.1182/blood-2025-87

Published: 2025

Journal Articles

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Zhongxun Shi, Fei Huang, Yu Chen, Chun Qiao, Rong Wang, Yan Wang, Jianyong Li, Lei Fan, Wenyi Shen

Blood (2025) 146 (Supplement 1): 7362.

https://doi.org/10.1182/blood-2025-7362

Published: 2025

Journal Articles

Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study

Li-Yang Shiau, Chien-Yun Chen, Hao-Yuan Wang, Hung-Cheng Tsai, Sunny Ssu-Yu Chen, Tina Ting-An Lin, Yi-Lin Chiang, Po-Shen Ko

Blood (2025) 146 (Supplement 1): 3959.

https://doi.org/10.1182/blood-2025-3959

Published: 2025

Journal Articles

Evaluation of ims-IP assay for the detection and typing of monoclonal immunoglobulins by mass spectrometry.

Yu Chen, Min Yang, Jie Jin, Haitao Meng

Blood (2025) 146 (Supplement 1): 7869.

https://doi.org/10.1182/blood-2025-7869

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Disease burden and treatment patterns in patients with previously treated primary immune thrombocytopenia (ITP): A retrospective study using administrative claims data in the United States

Joao Da Silva, Yu-Chen Yeh, Firas Dabbous, Carlos E Bertaglia Goncalves, Sarah Hale, Qian Li, Mei Lu, Sean Sana, Dorothy Romanus

Blood (2025) 146 (Supplement 1): 7990.

https://doi.org/10.1182/blood-2025-7990

Published: 2025

Journal Articles

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Blood (2025) 146 (1): 76–88.

https://doi.org/10.1182/blood.2024027689

Published: 2025

Includes: Supplemental data

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2024-203522

Published: 2024

Journal Articles

Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

Mark A Currier, Allen Reha, Brian Hutzen, Pin-Yi Wang, Chun-yu Chen, Andrea Glaspell, Siddhi Nath Paudel, Akila S Venkataramany, Debashree Das, Danielle Hanlon, Allan A. Kaspar, Samit Varma, Brian K. Kaspar, Jacob G. Scott, Pablo Morales, Peter Ralph, Tonny Johnson, Tania L. Weiss, Timothy P Cripe

Blood (2024) 144 (Supplement 1): 1056.

https://doi.org/10.1182/blood-2024-198463

Published: 2024

Journal Articles

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

Bernice Matusow, Sadegh Saghafinia, Pei Pei Li, Amanda Kohler, Pan-Yu Chen, Christine Nichols, Parmveer Singh, Kerry Inokuchi, Jackie M. Walling, Gideon Bollag

Blood (2024) 144 (Supplement 1): 1908.

https://doi.org/10.1182/blood-2024-208181

Published: 2024

Journal Articles

iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Blood (2024) 144 (Supplement 1): 4790.

https://doi.org/10.1182/blood-2024-205086

Published: 2024

Journal Articles

Discovery of the Unique GMP-Grade iPSC Clones That Give Rise to Functional, High Purity, Matured CD8 Alpha Beta T or Gamma Delta T with Exponential Expansion Capacity

Blood (2024) 144 (Supplement 1): 7195.

https://doi.org/10.1182/blood-2024-203106

Published: 2024

Journal Articles

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Jennifer A. Woyach, Danielle M. Brander, Boyu Hu, Kerry A. Rogers, Zulfa Omer, Deborah M. Stephens, Andrea Sitlinger, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Kewei Shang, John C. Byrd

Blood (2024) 144 (Supplement 1): 4622.

https://doi.org/10.1182/blood-2024-205775

Published: 2024

Journal Articles

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Juan Miguel Bergua Burgues, Kristin Koenig, Pau Montesinos, Dale L. Bixby, Patrick W. Burke, Naval Daver, Stephen P. Anthony, Fenlai Tan, Yi Chen, Yu Chen, Ignacio Casas Aviles, Emily K Curran

Blood (2024) 144 (Supplement 1): 6009.

https://doi.org/10.1182/blood-2024-208792

Published: 2024

Journal Articles

Pre-Clinical Evaluation of a New-Generation Orally Bioavailable Dual Bcl-2/Bcl-Xl Inhibitor LP-118 in Mantle Cell Lymphoma

Ling-Ling Lee, Cong Zhu, Brianna Feldmeier, Yao Chen, Wenyu Li, Yu Chen, Stephen P. Anthony, Yue Shen, Fenlai Tan, Yi Chen, Bing Dai

Blood (2023) 142 (Supplement 1): 3640.

https://doi.org/10.1182/blood-2023-180190

Published: 2023

Journal Articles

Venetoclax Combined with Azacitidine and Homoharringtonine in Adults with Secondary Acute Myeloid Leukemia

Fei Huang, Yu Chen, Zhongxun Shi, Huijun Huang, Jianyong Li, Wenyi Shen

Blood (2023) 142 (Supplement 1): 5962.

https://doi.org/10.1182/blood-2023-186713

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Triptonide and bortezomib synergistically inhibit multiple myeloma by enhancing DNA damage through blocking TRIP13-mediated DNA repair

Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity

High FDX1 expression enhances the sensitivity of multiple myeloma cells to elesclomol

Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study

Evaluation of ims-IP assay for the detection and typing of monoclonal immunoglobulins by mass spectrometry.

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Disease burden and treatment patterns in patients with previously treated primary immune thrombocytopenia (ITP): A retrospective study using administrative claims data in the United States

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Discovery of the Unique GMP-Grade iPSC Clones That Give Rise to Functional, High Purity, Matured CD8 Alpha Beta T or Gamma Delta T with Exponential Expansion Capacity

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Pre-Clinical Evaluation of a New-Generation Orally Bioavailable Dual Bcl-2/Bcl-Xl Inhibitor LP-118 in Mantle Cell Lymphoma

Venetoclax Combined with Azacitidine and Homoharringtonine in Adults with Secondary Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only